Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Resignation of Director

 Mr. Sunil Bafna (DIN: 01458225), Independent Director has resigned from the Board of the Company vide his resignation letter dated 10th September 2020 due to pre-occupation. The letter as received by the Company is enclosed herewith as Annexure- A. Accordingly, Mr. Sunil Bafna ceased to be an Independent Director from the Board of the Company w.e.f. 10th September, 2020. The above may please be treated as compliance of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule III of said Regulations. We request you to kindly take note of the above.
11-09-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Appointment of Ms. Shanmugam Hemalatha (DIN:02714329) as Whole-Time Director w.e.f from 10.09.2020. Appointment of Mr. Battu Harish Laxmaiah (DIN: 06390117) as an Additional Director (Non-executive Director- Independent) w.e.f from 10.09.2020. Appointment of Mrs. Akilapriya Chandrashekar Raju (DIN: 07590312) as an Additional Director (Non-executive Director Independent) with effect from 10.09.2020. Resignation of Mr. Paras Bafna (DIN: 01933663) as Whole-Time Director as well as Director of the Company with effect from 10.09. 2020 Resignation of Mrs. Sabitha (DIN:02643259) as Whole-Time Director (Woman) as well as Director with effect from 10th September 2020. Resignation of Mr. Sunil Bafna (DIN:01458225) as an Independent Director with effect from 10.09.2020. Resignation of Mr. Mahaveer Chand Bafna (DIN: 01458211) as Managing Director as well as Director with effect from 10.09.2020. Appointment of Mr. Mahaveer Chand Bafna as Chief Executive Officer with effect from 10.09.2020.
10-09-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Allotment

 Preferential Allotment of 21290701 equity shares of Rs.10/ each at a price of Rs.26/- to SRJR Lifesciences LLP pursuant to NCLT Order under Insolvency and Bankruptcy Code 2016.
10-09-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Financial Results For 30Th June 2020

 1. UN-AUDITED FINANCIAL RESULT Approval of un-audited financial results of the Company for the quarter ending 30th June 2020. Please find attached Limited Review Report from the statutory auditor of the Company M/s. R. Sathyanarayanan & Co. 2. Preferential Allotment of 21290701 equity shares of Rs.10/ each at a price of Rs.26/- to SRJR Lifesciences LLP pursuant to NCLT Order under Insolvency and Bankruptcy Code 2016.
10-09-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Outcome Of The Board Meeting Held On 10Th Sep 2020

 The Board of Directors of the Company at their meeting held on today inter-alia transacted the following business.:- 1. UN-AUDITED FINANCIAL RESULT Approval of un-audited financial results of the Company for the quarter ending 30th June 2020. Please find attached Limited Review Report from the statutory auditor of the Company M/s. R. Sathyanarayanan & Co. 2. Preferential Allotment of 21290701 equity shares of Rs.10/ each at a price of Rs.26/- to SRJR Lifesciences LLP pursuant to NCLT Order under Insolvency and Bankruptcy Code 2016
10-09-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Financial Results, Preferential Allotment And Other Business Matter

 BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/09/2020 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Thursday, 10th September 2020 online through video conferencing, to inter alia consider and adopt un-audited financial results for the first quarter ending 30th June 2020 and preferential allotment of 21290701 shares to SRJR Lifesciences LLP pursuant to the Order passed by NCLT, Chennai as part of approved Resolution Plan under IBC 2016 and any other business with the permission of the Chair. The Company has already received In-principle approval from NSE for preferential allotment and awaiting In-principle approval from BSE. Further in accordance with the Code of Conduct for prevention of Insider Trading pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the trading window for dealing in securities of the Company shall remain closed until 48 hours after the financial results approved at the meeting are made public.
01-09-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayBAFNA PHARMACEUTICALS LTD. 2CINL24294TN1995PLC030698 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: JITENDRA KUMAR PAL Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: M SRIDHAR Designation: Chief Financial Officer EmailId: [email protected] Date: 12/08/2020 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
12-08-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Voting Results And Scrutinizer Report For The AGM Held On 31St July 2020

 Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Please find attached voting results for the AGM held on 31st July 2020 under Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and scrutinizer report.
01-08-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

 Bafna Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here
01-08-2020
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Proceedings Of 25Th Annual General Meeting Held On 31St July 2020

 Please be informed that the 25th AGM of the Company was held on 31st July 2020 through Video Conferencing ('VC')/ Other Audio Visual Means ('OAVM') at 12.00 Noon IST. In this regard please find attached the summary of the proceedings of the AGM of the Company. The voting results of the 25th Annual General Meeting of the Company along with the Scrutinizer report will be shared shortly. The 25th Annual General Meeting of the Company was concluded at 01.00 P.M. IST We request you to take the above information on your record
31-07-2020
Next Page
Close

Let's Open Free Demat Account